Efficacy and palatability of the developed polyethylene glycol-based formula for the treatment of children with functional constipation

Table 5 Adverse events during the intervention period (n = 52), n (%)

Adverse events	PEG-Chula (n = 26)	Commercial PEG (n = 26)
Number of patients who reported adverse events	5 (19.23)	3 (11.54)
Mild	5 (19.23)	3 (11.54)
Moderate	0	0
Severe	0	0
Any adverse events
Diarrhoea	3 (11.54)	2 (7.69)
Abdominal pain	2 (7.69)	1 (3.85)

PEG: Polyethylene glycol.